Johnson and Johnson will be the biggest pharmaceutical in the world when it spins off its consumer health business. The company's top three drugs are around 22%. And that means they have a really diversified pharma pipeline, which is what I like the most about J&J. But the biggest risk for me actually is just that the company depends so much on sales of one or two drugs,. It's now $51 in a bit on Monday, but I hope to have it by next week.
In today's episode, we share 5 dividend growth stocks we are buying during the current market dip. Besides that we speak a bit about the turmoil in the market around $SVIB because we got several questions about this. We hope you enjoy this episode!
Join the conversation: https://www.facebook.com/groups/dividendtalk